Immunocompromised Patients
Conditions
Keywords
Covid-19, SARS-CoV-2, Immunocompromised, Monoclonal Antibodies, Mortality
Brief summary
Absence of anti-SARS-CoV-2 vaccine response or insufficient vaccine response may occur in immunocompromised patients. Being at high risk of a severe form of Covid-19, they may be eligible to receive recombinant anti-SARS-CoV-2 monoclonal antibodies (mAbs). This study aims to describe patients who received anti-SARS-CoV-2 mAbs, in prophylaxis and/or curative of covid-19, and to analyze the hospitalization and mortality rates. This study is multicentric on all the university hospitals of Paris (AP-HP).
Interventions
OTHERData collection
Anti SARS-CoV-2 Monoclonal Antibodies: casirivimab-imdevimab (Ronapreve) OR bamlanivimab-etesevimab OR tixagevimab-cilgavimab (Evusheld) OR regdanvimab OR sotrovimab (Xevudy) OR adintrevimab
Sponsors
Assistance Publique - Hôpitaux de Paris
URC-CIC Paris Descartes Necker Cochin
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult ≥ 18 years old * Patients who received at least one administration of the following therapies: casirivimab-imdevimab, bamlanivimab-etesevimab, tixagevimab-cilgavimab, regdanvimab, sotrovimab or adintrevimab
Exclusion criteria
* Patients opposed to the collection of their personal data
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mortality rate | 29 days after last administration | Covid-19 mortality : Explore the mortality rate related to COVID-19 in patients treated with anti-SARS-CoV-2 monoclonal antibodies |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Hospitalizations rate | 29 days after last administration | Explore the hospitalizations rate related to COVID-19 in patients treated with anti-SARS-CoV-2 monoclonal antibodies in prophylaxis |
| Mortality rate | 29 days after last administration | Explore the mortality rate related to COVID-19 in patients treated with anti-SARS-CoV-2 monoclonal antibodies in prophylaxis |
| Proportion of hospitalizations | 29 days after last administration | Proportion of hospitalizations from all causes, in patients treated prophylactically and curatively by anti-SARS-CoV-2 monoclonal antibodies |
| Proportion of deaths | 29 days after last administration | Proportion of deaths from all causes, in patients treated prophylactically and curatively by anti-SARS-CoV-2 monoclonal antibodies |
Countries
France
Contacts
PRINCIPAL_INVESTIGATORJeremie Zerbit, PharmD
Pharmacy Department, Cochin Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP)
Outcome results
None listed